CPhI News

Expert poll highlights strength of US pharma sector and advances by emerging markets.

The new API for hypothyroidism treatment will replace the hormones that are ineffectively produced by the human thyroid gland.

During CPhI Worldwide in Frankfurt, Germany, Datwyler launched its Starter Pack, which features its Omni Flex stoppers and Prime Caps along with Schott’s adaptiQ vials, targeted at clients looking to tackle small quantity component needs.

The company introduced its new advanced elastomer, the 4040/40 formulation, and a new line extension of its AccelTRA component program, AccelTRA Select, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.

The winners were announced during day one of CPhI Worldwide.

On the last day of CPhI Worldwide (Thursday Nov. 7, 2019), several experts will examine the potential role of three-dimensional printing within medicines, particularly in light of the shift in the industry from volume to value.

Avantor’s Senior Vice-President of Business Development and Commercial Operations (Claudia Berrón) will be presenting trends in raw material data mining and sharing within biopharma on the last afternoon of CPhI Worldwide (Thursday Nov. 7, 2019).

On Wednesday Nov. 6, 2019, Dr. Derek Duncan from Lighthouse Instruments will summarize the current state of container closure integrity testing (CCIT) in the bio/pharma industry and will outline a framework for the development of a holistic testing strategy.

Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.

The second part of CPhI’s annual report has projected that the biologic manufacturing capacity of Europe will exceed that of the United States by 2023, as a result of the rising number of commercially approved biologics.

According to the third part of the CPhI annual report, a lack of cell and gene expertise may be a drag factor on the sector and a spike in biological therapeutics development is driving bio demand in China.

The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times.

Ashland will be presenting new devices at booth 102B13 at CPhI Worldwide.

Dr. Ger Brophy, executive vice president, Biopharma Production for Avantor, will deliver the keynote address at the conference and Claudia Berrón, senior vice president, Business Development and Commercial Operations for Avantor, will discuss on leveraging biopharma 4.0 to reconstruct the biopharma supply chain and manufacturing practices.

The company will showcase its RayDyLyo all-plastic capping solution, which works in conjunction with SCHOTT’s adaptiQ ready-to use (RTU) vials and groninger Nestfillers by providing maximum flexibility for fill/finish operations.

During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).

To address the potential medicines of tomorrow, a panel of experts will discuss emerging therapies and the potential of developing new medicines and repurposing old medicines on Tuesday Nov. 5, 2019 at CPhI in Frankfurt, Germany.

The company believes the investment will improve its support of clients’ research, development, and clinical manufacturing needs by expanding its development and manufacturing capacity.

The company will be exhibiting several solutions and innovations including its HarleNIR vision system, Yudoo software suite, and Ubiquity software.

The company will aim to increase its employee headcount to meet the demand for one-stop-shop drug products manufacturing services.

Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.

The company will showcase new solutions for isolation technology systems, sterilization, and pharmaceutical freeze-drying applications at the event.

The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging.

The new device can inject a range of drugs of different viscosities up to 35cP and different fill volumes up to 1mL.

The CPhI Pharma Index points to Germany as having consolidated itself into a leading pharma industry.

The company will debut its new brand name, ALPLApharma, and its new childproof closure, the CRC justONE, at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.

The new location is the first step in the company’s plan to invest in the North American market over the next two years.

Bikash Chatterjee, president and chief science officer at Pharmtech Associates and Girish Malhotra, president of EPCOT International, touch upon how manufacturing could be revolutionized by new technologies if regulators evolve to prevent hindering future innovation.